Extract
Surgical lung biopsy (SLB) in diffuse parenchymal lung disease (DPLD) has been associated with significant in-hospital mortality (16% for non-elective patients, 1.7% for elective patients, overall 6.4%) [1, 2]. Overall 30-day mortality from SLB is reported at 1.5–4.5% from case series and 2.4% from a large European database [3]. Transbronchial cryobiopsy (TBC) has been proposed as a safer alternative to SLB for diagnosis of DPLD [4]. Existing studies on TBC report immediate procedural complications, but data on mortality at 30 and 90 days is sparse [2].
Abstract
This study suggests 30- and 90-day mortality after transbronchial cryobiopsy is higher than reported, confirming concerns raised about safety in advanced diffuse lung disease. Keen attention towards patient selection and procedural planning is warranted. http://bit.ly/2ySoZNq
Footnotes
Conflict of interest: J. Pannu has nothing to disclose.
Conflict of interest: L.J. Roller has nothing to disclose.
Conflict of interest: F. Maldonado reports grants from ERBE research funding, outside the submitted work.
Conflict of interest: R.J. Lentz has nothing to disclose.
Conflict of interest: H. Chen has nothing to disclose.
Conflict of interest: O.B. Rickman has nothing to disclose.
- Received February 18, 2019.
- Accepted June 25, 2019.
- Copyright ©ERS 2019
LIBRARY USERS
Log in through your institution
Purchase access
